rethinkTHC Search
Menu
Study breakdown

Medical cannabis did not significantly affect quality of life in Illinois opioid alternative program

Cross SectionalPreliminary evidence
The takeaway

Among 860 participants in Illinois' Opioid Alternative Pilot Program, quality of life averaged between "good" and "fair" with no significant difference between cannabis users and non-users.

People in opioid alternative programs, policymakers, and pain management clinicians.

Quality of life: users 2.86 vs non-users 2.85 (p=0.92)

What the researchers found

Quality of life averaged 2.86 (between "good" and "fair") across the full sample, with no significant difference between non-users (2.85) and cannabis users (2.86, p=0.92). Logistic regression showed cannabis use within the past year was not significantly associated with quality of life (OR 1.33, 95% CI 0.85-2.08, p=0.21).

Why it matters

Quality of life is a key outcome for opioid alternative programs. The null finding, like the companion psychological well-being study, suggests cannabis substitution is neither dramatically beneficial nor harmful for overall quality of life, though the "good to fair" average across both groups indicates room for improvement.

The numbers in context

860 participants. QoL: non-users 2.85, users 2.86, p=0.92. Logistic regression: OR 1.33 (95% CI 0.85-2.08, p=0.21). Average age 47, 60% male, 67% married.

How the study worked

Same cohort as the psychological well-being study (RTHC-06372): survey of OAPP enrollees from February-July 2019. Cannabis users (n=626) vs non-users (n=234) were compared on quality of life using ordered logistic and backward stepwise regression.

What this study cannot tell us

Same limitations as RTHC-06372: cross-sectional, self-selected, no baseline, limited sensitivity of a single QoL measure. Pain being a qualifying condition may have created a floor effect on quality of life that cannabis could not overcome.

How to read the evidence

Cross-sectional survey with no baseline measurement, same cohort and limitations as companion study.

When this study was published

Published in 2025, using 2019 survey data.

The bigger picture

Taken together with the companion study on psychological well-being, the picture for Illinois' OAPP is one of neutrality: cannabis substitution appears to be a lateral move for overall well-being and quality of life. The real benefit may lie in reduced opioid use and its associated risks rather than in improved subjective quality of life.

Questions still open

  • Would quality of life improve with longer cannabis use? Is the real benefit of opioid substitution programs better measured by reduced opioid-related harms rather than quality of life? Would disease-specific quality of life measures be more sensitive?

Common questions

Should I expect medical cannabis to improve my quality of life?
In this opioid alternative program, cannabis use was not associated with better or worse quality of life compared to non-use. The benefit may lie more in avoiding opioid risks than in subjective quality of life improvement.

Read the original research

The association of medical cannabis use with quality of life in Illinois' opioid alternative pilot program.

Journal of epidemiology and population health, 73(1), 202803

Citation

Dubois, Cerina; Bobitt, Julie; Ding, Lei; Eurich, Dean T; Knapp, Ashley A; Jordan, Neil. (2025). The association of medical cannabis use with quality of life in Illinois' opioid alternative pilot program.. Journal of epidemiology and population health, 73(1), 202803. https://doi.org/10.1016/j.jeph.2024.202803

Explore the wider topic